Screener

Eligibility screening

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Sponsored by SEED Therapeutics, Inc.Study detailsClinicalTrials.gov

6 US sites in CA, MA, NY, TX

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.